Mitoquinone mesylate targets SARS-CoV-2 infection in preclinical models.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
23 Jun 2022
23 Jun 2022
Historique:
pubmed:
3
3
2022
medline:
3
3
2022
entrez:
2
3
2022
Statut:
epublish
Résumé
To date, there is no effective oral antiviral against SARS-CoV-2 that is also anti-inflammatory. Herein, we show that the mitochondrial antioxidant mitoquinone/mitoquinol mesylate (Mito-MES), a dietary supplement, has potent antiviral activity against SARS-CoV-2 and its variants of concern Mitoquinone/mitoquinol mesylate has potent antiviral and anti-inflammatory activity in preclinical models of SARS-CoV-2 infection.
Identifiants
pubmed: 35233569
doi: 10.1101/2022.02.22.481100
pmc: PMC8887067
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAAA NIH HHS
ID : R01 AA026914
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG059502
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA237401
Pays : United States
Organisme : NIGMS NIH HHS
ID : R25 GM055052
Pays : United States